Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
Researchers found a new vulnerability in cancer cells that resist EGFR drugs, suggesting a combination therapy approach that could delay treatment resistance in lung cancer.
Drug-tolerant persister (DTP) cells are a key driver of acquired resistance to EGFR TKI therapy in NSCLC, and this Cancer Cell study identifies TROP2 as a targetable vulnerability in these cells. Targeting TROP2 pharmacologically delayed resistance emergence, suggesting TROP2 ADC combination with EGFR TKIs as a clinically testable strategy.
What the study was
- Study design
- Preclinical mechanistic study with likely patient sample validation (Cancer Cell journal standard)
- Population
- NSCLC patients with EGFR mutations receiving TKI therapy (patient samples + in vitro/in vivo models)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Cell
Why it surfaced
Cancer Cell publication identifying TROP2 as a mechanistic target to delay EGFR TKI resistance in NSCLC. NSCLC acquired resistance is a major unresolved clinical problem; TROP2 ADCs are already FDA-approved in breast/urothelial cancers, making this combination rationale immediately translatable to clinical investigation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.